Cramer, Daniel

Open Protocols

Protocol Name Investigatory Role Biomarkers Data Collections
Pre-operative plevic mass study Leading 0 0

Closed Protocols

Protocol Name Investigatory Role Biomarkers Data Collections
Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer Leading 0 0
Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement Involved 28 0
Biomarker Reference Sets for Cancers in Women Leading 0 0
EDRN Resource Network Exchange Involved 0 0
Ovarian Cancer Screening Pilot Trial In High Risk Women Involved 0 0
PLCO Ovarian Phase III Validation Study Leading 50 1
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study Leading 55 2


Publication NamePubMed IDJournal
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. 18349277 Cancer Epidemiol Biomarkers Prev
Blood and urine markers for ovarian cancer: a comprehensive review. 15322314 Dis Markers
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. 15894662 Cancer Epidemiol Biomarkers Prev
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. 12912935 Clin Cancer Res
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. 14581349 Clin Cancer Res
Non-genomic biomarkers of risk in ovarian cancer. 18057519 Dis Markers
Osteopontin as a potential diagnostic biomarker for ovarian cancer. 11926891 JAMA
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. 15161704 Clin Cancer Res
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. 21372036 Cancer Prev Res (Phila)
Pooling of case specimens to create standard serum sets for screening cancer biomarkers. 17301268 Cancer Epidemiol Biomarkers Prev
Promoter hypermethylation profile of ovarian epithelial neoplasms. 16061849 Clin Cancer Res
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. 11584061 J Natl Cancer Inst
Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. 17245808 J Bioinform Comput Biol
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. 16428483 Clin Cancer Res
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. 19008269 BMJ
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). 19282241 Lancet Oncol
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. 18061248 Gynecol Oncol
Urokinase-type plasminogen activator receptor: a beacon of malignancy? 18794069 Clin Cancer Res
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. 18245537 Clin Cancer Res


ovarian cancer
Dr. Cramer investigates epidemiologic and genetic risk factors for ovarian cancer as well as early detection biomarkers. The latter studies principally involve the use of microarrays to identify upregulated genes and done in conjunction with Dr. Mok as well as use of SELDI mass spectrometry done in conjunction with Dr. Skates.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Photograph of Cramer, Daniel
Brigham and Womens Hospital
M.D., Sc.D.
(617) 732-4899
Person ID
EDRN Title
EDRN Associate Member
To update contact information, please visit the Data Management and Coordinating Center .